Armistice Capital, LLC Macrogenics Inc Transaction History
Armistice Capital, LLC
- $6.56 Billion
- Q1 2025
A detailed history of Armistice Capital, LLC transactions in Macrogenics Inc stock. As of the latest transaction made, Armistice Capital, LLC holds 6,296,000 shares of MGNX stock, worth $9.26 Million. This represents 0.12% of its overall portfolio holdings.
Number of Shares
6,296,000
Previous 6,276,000
0.32%
Holding current value
$9.26 Million
Previous $20.4 Million
60.8%
% of portfolio
0.12%
Previous 0.29%
Shares
13 transactions
Others Institutions Holding MGNX
# of Institutions
117Shares Held
51.4MCall Options Held
45.1KPut Options Held
143K-
Bellevue Group Ag Kuesnacht, V89.93MShares$14.6 Million0.29% of portfolio
-
Black Rock Inc. New York, NY5.4MShares$7.94 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.21MShares$6.19 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT3.25MShares$4.78 Million0.02% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.18MShares$4.67 Million0.25% of portfolio
About MACROGENICS INC
- Ticker MGNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,458,800
- Market Cap $90.3M
- Description
- MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...